Following the remarkable success recorded for the mRNA Covid-19 vaccines, BioNTech has announced the launch of a project aimed at developing the first mRNA-based malaria vaccine with the clinical trial planned for the end of 2022. The German biotech company—which together with its US partner Pfizer developed the first-ever approved mRNA vaccine—now plans to use this technology to address this killer disease.If successful, the project will result in a malaria vaccine that may help to reduce the high rate of malaria deaths whose main impact is felt in Africa. Africa accounted for 94% of the 229 million cases of malaria and 409,000 malaria deaths in 2019, according to WHO.The project supported
Hence then, the article about biontech aims to develop the first mrna malaria vaccine as well as the capacity to produce it in africa was published today ( ) and is available onQuartz ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( BioNTech aims to develop the first mRNA malaria vaccine as well as the capacity to produce it in Africa )